News

The partnership will focus on utilizing Quotient’s integrated service portfolio to support the rapid development of CytoAgents’ lead COVID-19 drug candidate, GP1681, for Phase I and II in

The CAN-COVID study will assess the efficacy of using canakinumab for the treatment of a type of severe immune overreaction known as cytokine release syndrome (CRS) in people

Merck has also entered into an agreement with the Biomedical Advanced Research and Development Authority (BARDA), part of the office of the Assistant Secretary for Preparedness and Response

The company’s AAVSmartLibrary and associated technology are said to be used for developing AAV capsids for enhanced tissue tropism, manufacturability, and pre-existing immunity. The collaboration will make use

Moderna has received initial feedback from the FDA on the design of the planned Phase 2 study, which is expected to begin in the second quarter of 2020.

The breakthrough therapy status will allow using of mobocertinib by patients with epidermal growth factor receptor (EGFR) exon 20 insertion mutations whose disease has advanced on or after

The data will be presented as a virtual poster at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting I. This ongoing study is an open

Lynparza delivered the result in the PROfound trial, which is being carried out in men with metastatic castration-resistant prostate cancer (mCRPC) who have a homologous recombination repair gene

If approved for these indications, SIMPONI ARIA would be the first anti-tumor necrosis factor (TNF)-alpha biologic agent administered by intravenous infusion available for the treatment of these juvenile